Rubicatin and rubicatin: same drug, same efficacy

Introduction: Rubicatin and rubicatin are different names for the same drug. Rubicatin is also called rubicidine and rubicatin. Whether it is called rubicidin or rubicatin, its effect is consistent in the treatment of specific types of lung cancer (such as metastatic small cell lung cancer, especially patients who have progressed after platinum-based chemotherapy).

Basic information about rubitidine

was approved by the U.S. Food and Drug Administration on June 15, 2020, for the treatment of adult patients with metastatic small cell lung cancer who have disease progression during or after platinum-based chemotherapy. Clinical trials show that rupitidine has good efficacy in metastatic small cell lung cancer.

Pharmacological effects

Rupitidine is an alkylating anti-tumor drug that can inhibit the active transcription of protein-coding genes on DNA, causing cell cycle disorders and inducing cell death. The activity of rubitidine has been studied in a number of solid tumors, showing not only promising results but also a good safety profile. In relapsed SCLC, the drug showed encouraging activity both as a single agent and in combination with doxorubicin, paclitaxel, or irinotecan.

Efficacy Analysis

On June 15, 2020, the U.S. Food and Drug Administration granted accelerated approval to rupitidine for the treatment of adult patients with metastatic small cell lung cancer (SCLC) whose disease has progressed during or after platinum-based chemotherapy. Its efficacy was demonstrated in a study enrolling 105 patients with metastatic SCLC who had disease progression during or after platinum-based chemotherapy. Among 105 patients, the ORR was 35% and the median duration of response was 5.3 months. According to independent review committee data, the ORR was 30% and the median duration of response was 5.1 months.

Adverse reactions

The most common adverse reactions of rubitidine include laboratory abnormalities, which are bone marrow suppression, increased blood sugar, nausea, decreased appetite, increased alanine aminotransferase, decreased albumin, fatigue, increased creatinine, constipation, dyspnea, decreased sodium, vomiting, cough, increased aspartate aminotransferase, musculoskeletal pain, decreased magnesium, and diarrhea.